DDI2–NFE2L1 Axis: Ubiquitin-Proteasome Control of Ferroptosi
2026-04-20
Activating the DDI2–NFE2L1 Pathway to Regulate Ferroptosis: Mechanistic Insights and Research Tools
Study Background and Research Question
Ferroptosis is a regulated form of cell death distinct from apoptosis, marked by iron-dependent lipid peroxidation and membrane rupture. It is increasingly recognized as a contributing factor in neurodegeneration, cancer, and tissue injury syndromes (paper). While glutathione peroxidase 4 (GPX4) is a well-established guardian against ferroptosis, recent evidence suggests that adaptive responses in protein homeostasis, specifically the ubiquitin-proteasome system (UPS), play a protective role. The reference study set out to clarify how the UPS adapts to ferroptotic stress and the molecular mechanisms underlying this process, focusing on the transcription factor NFE2L1 and its upstream regulator, the aspartyl protease DDI2.Key Innovation from the Reference Study
The principal innovation is the identification of a feedback mechanism wherein oxidative lipid stress, characteristic of ferroptosis, inhibits proteasomal activity and induces global protein hyperubiquitylation. The study reveals that the activation of NFE2L1—typically tethered to the endoplasmic reticulum—requires proteolytic cleavage by DDI2. This cleavage is crucial for the upregulation of proteasome subunit genes, which in turn restores proteasomal function under ferroptotic conditions. Notably, disruption of this DDI2–NFE2L1 axis sensitizes cells to ferroptosis, and pharmacological inhibition of DDI2 (e.g., with nelfinavir) can modulate this sensitivity (paper).Methods and Experimental Design Insights
The authors employed an unbiased proteomics workflow to map ubiquitylation sites following induction of ferroptosis with RSL3, a specific GPX4 inhibitor. Proteasomal activity was assessed by biochemical assays, while NFE2L1 activation status was measured by immunoblotting for its proteolytically processed form and by quantifying proteasome subunit gene expression. DDI2 knockout cell lines were generated via CRISPR/Cas9 to dissect the necessity of DDI2 in NFE2L1 activation. Complementary experiments tested the effects of nelfinavir, a clinical HIV-1 protease inhibitor now recognized as a DDI2 inhibitor, on ferroptotic sensitivity.Protocol Parameters
- ferroptosis induction assay | RSL3, 1–2 μM | human cell lines | Direct GPX4 inhibition to induce ferroptosis | paper
- proteasome activity assay | fluorogenic peptide substrate, 20–50 μg protein | cell lysates | Quantifies proteasome catalytic function | paper
- NFE2L1 activation detection | immunoblot for cleaved NFE2L1 | wild-type vs. DDI2 KO cells | Determines DDI2-dependent NFE2L1 processing | paper
- ubiquitylation site mapping | tandem mass spectrometry | RSL3-treated cells | Global assessment of UPS adaptation | paper
- DDI2 inhibition | nelfinavir, 5–20 μM | cell culture | Chemical blockade of DDI2-mediated NFE2L1 activation | paper
- cell viability under ferroptosis | CellTiter-Glo, 24–48 h post-induction | DDI2/NFE2L1-competent vs. deficient lines | Quantifies ferroptotic sensitivity | paper
- HIV protease inhibition assay | nelfinavir, 10–50 nM | HIV-1 infected CEM cells | Standard antiviral benchmark | product_spec
Core Findings and Why They Matter
The study demonstrates that ferroptosis, as triggered by GPX4 inhibition, leads to proteasomal suppression and hyperubiquitylation of cellular proteins. In wild-type cells, this stress is mitigated by DDI2-mediated cleavage of NFE2L1, which translocates to the nucleus and upregulates proteasome subunit genes, restoring proteostasis (paper). In DDI2-deficient cells, NFE2L1 remains inactive, proteasomal function collapses, and cells become highly susceptible to ferroptosis. Importantly, pharmacological inhibition of DDI2 using nelfinavir recapitulates the genetic loss-of-function phenotype, supporting a druggable axis for sensitizing cells to ferroptosis. This mechanism is of particular interest for cancer therapy, where induction of ferroptosis is a promising strategy to eliminate resistant cells.Comparison with Existing Internal Articles
Recent internal reviews have highlighted the emerging utility of nelfinavir beyond its antiretroviral indication, particularly in the context of protein homeostasis and cell death modulation:- Nelfinavir Mesylate at the Nexus of HIV-1 Protease Inhibition and Ferroptosis synthesizes evidence for nelfinavir’s dual role as both a benchmark HIV-1 protease inhibitor and a modulator of the DDI2–NFE2L1 axis, echoing the mechanistic findings of the reference paper.
- Nelfinavir Mesylate: Beyond HIV Protease Inhibition provides in-depth analysis of nelfinavir’s impact on proteostasis, supporting its application in dissecting DDI2–NFE2L1 signaling in ferroptosis research.